Chow Yin Wong
Overview
Explore the profile of Chow Yin Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tay V, Tan S, Wong C, Leong L
J Korean Soc Radiol
. 2025 Feb;
86(1):160-165.
PMID: 39958502
The sternalis muscle is a rare supernumerary muscle representing a normal anatomical variant in the anterior thoracic musculature. Due to wide variation in its morphology and relative unfamiliarity among radiologists,...
2.
Tan H, Tan P, Leong L, Tan V, Tan B, Lim S, et al.
Cancer Med
. 2023 Mar;
12(10):11408-11416.
PMID: 36999966
Background: Encapsulated papillary carcinoma of the breast is rare, making difficult diagnosis and resulting in patients undergoing excision biopsy before definitive surgery. Evidence-based guidelines are sparse. We would like to...
3.
Chan C, Poh B, Wong C, Kwah R, Leong L
Ann Acad Med Singap
. 2022 Oct;
51(9):589-590.
PMID: 36189707
No abstract available.
4.
Lim J, Sim Y, Ngeow J, Yuen J, Tan V, Tan B, et al.
ANZ J Surg
. 2022 Apr;
92(6):1440-1446.
PMID: 35470542
Introduction: Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to...
5.
Sim Y, Lim C, Phyu N, Tan K, Chew L, Wong C, et al.
Front Oncol
. 2022 Apr;
12:835320.
PMID: 35433431
Introduction: Statins, HMG-CoA reductase inhibitors, are commonly used cholesterol-lowering medications which are also increasingly recognized to have anti-cancer properties for various cancers, including breast cancer. Most clinical evidence supports a...
6.
Bong T, Tan J, Ho J, Tan P, Lau W, Tan T, et al.
J Breast Cancer
. 2022 Feb;
25(1):37-48.
PMID: 35199500
Purpose: This study identified factors predicting malignant upgrade for atypical ductal hyperplasia (ADH) diagnosed on core-needle biopsy (CNB) and developed a nomogram to facilitate evidence-based decision making. Methods: This retrospective...
7.
Loo S, Toh L, Xie W, Pathak E, Tan W, Ma S, et al.
Sci Adv
. 2021 Oct;
7(41):eabh2443.
PMID: 34613780
Cell state transitions control the functional behavior of cancer cells. Epithelial-to-mesenchymal transition (EMT) confers cancer stem cell-like properties, enhanced tumorigenicity and drug resistance to tumor cells, while mesenchymal-epithelial transition (MET)...
8.
Lim S, Kusumawidjaja G, Mohd Ishak H, Tan B, Tan S, Hamzah J, et al.
Breast Cancer Res Treat
. 2021 Aug;
189(3):837-843.
PMID: 34342766
Purpose: Studies that report equivalent oncologic outcomes of sentinel lymph node biopsy (SLNB) alone versus axillary lymph node dissection (ALND) for T1-2N1mi breast cancers are heavily weighted with patients who...
9.
Ng C, Nasir N, Loke B, Tay T, Thike A, Rajasegaran V, et al.
Mod Pathol
. 2021 Mar;
34(7):1320-1332.
PMID: 33727697
Breast fibroepithelial lesions are biphasic tumors which comprise the common benign fibroadenomas (FAs) and the rarer phyllodes tumors (PTs). This study analyzed 262 (42%) conventional FAs, 45 (7%) cellular FAs,...
10.
Tay T, Ng W, Ong K, Wong C, Tan B, Yong W, et al.
Breast J
. 2019 Dec;
26(5):937-945.
PMID: 31876337
Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease which is increasingly diagnosed through improved screening measures. Multiple prognostic scores have been devised to predict the risk...